Mitsubishi Chemical : Expiration of Marketing Alliance Agreement for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets NEW

March 4, 2024

Expiration of Marketing Alliance Agreement

for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "Mitsubishi Tanabe Pharma") and Daiichi Sankyo Company, Limited (Head Office: Chuo-ku, Tokyo; Representative Director, President: Hiroyuki Okuzawa; hereinafter, "Daiichi Sankyo") will expire the marketing alliance agreement for the selective DPP-4 inhibitor, "TENELIA® Tablets" and "TENELIA® OD Tablets" (both hereinafter, "TENELIA® Tablets/OD Tablets;" generic name: Teneligliptin Hydrobromide Hydrate), and the SGLT2 inhibitor, "CANAGLU® Tablets" (generic name: Canagliflozin Hydrate), on September 2, 2024, due to the expiration of the agreement.

Under the agreement, the distribution of TENELIA® Tablets/OD Tablets has been conducted by Daiichi Sankyo, whereas the distribution of CANAGLU® Tablets has been carried out by Mitsubishi Tanabe Pharma. Both companies have been jointly engaged in information provision of the products. With the expiration of the marketing alliance agreement, Daiichi Sankyo will transfer the distribution rights of TENELIA® Tablets/OD Tablets to Mitsubishi Tanabe Pharma and will end the information provision activities to medical institutions for all products, which are currently jointly conducted with Mitsubishi Tanabe Pharma.

Mitsubishi Tanabe Pharma and Daiichi Sankyo will cooperate to ensure the smooth transfer of the products, and from September 3, 2024, Mitsubishi Tanabe Pharma will independently carry out the marketing and information provision activities for TENELIA® Tablets/OD Tablets and CANAGLU® Tablets.

Daiichi Sankyo will continue to market CANALIA® Combination Tablets (combined TENELIA® and CANAGLU®) and both companies will continue to jointly engage in its co-promotion.

Through a stable supply of ethical drugs and prompt and appropriate information provision activities, Mitsubishi Tanabe Pharma and Daiichi Sankyo will continue contributing to the prevention and treatment of diseases and people's health in Japan.

1

Products:

TENELIA® Tablets 20 mg

TENELIA® Tablets 40 mg

TENELIA® OD Tablets 20 mg

TENELIA® OD Tablets 40 mg

CANAGLU® Tablets 100 mg

◆Contact information

Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group, Corporate Communications Div., Osaka Corporate Communications Dept.)

◆About Mitsubishi Tanabe Pharma Corporation

Founded in 1678, Mitsubishi Tanabe Pharma, the pharmaceutical division of Mitsubishi Chemical Group (MCG), is one of the oldest established pharmaceutical companies, centering on the prescription drug business. In its management policy "Forging the future," MCG has positioned healthcare as one of its most important strategic markets. Our company's MISSION is "A desired option for all who face their illness." To achieve this, we will focus on oncology, in addition to central nervous system, immuno-inflammatory diseases, and diabetes and renal diseases. In addition to Precision Medicine, which identifies a patient population with high efficacy and safety and provides a high level of satisfaction with treatment, we will also develop "around pill solutions" to address patient concerns, starting with treatment drugs, with a focus on prevention, pre-existing diseases, prevention of disease progression, and prognosis.

https://www.mt-pharma.co.jp/

◆About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information,

please visitwww.daiichisankyo.com.

2